Angiogenic factor with G-patch and FHA domain1 (AGGF1 or VG5Q) is a newly identified human angiogenic factor. The aim of this study was to explore AGGF1 expression level in gastric cancer and detect its correlation with the prognosis.
Background
Gastric cancer (GC) is one of the most aggressively malignant tumors of the digestive tract. Most patients have been in advanced stage at diagnosis and the effectiveness of surgery is limited. Invasion and metastasis is the main cause of death in patients with gastric cancer. Among the potential promoting factors, tumor angiogenesis plays an important role [1, 2] . Tumor angiogenesis is the basis of tumor growth and metastasis. Therefore, it an important focus in the study of angiogenesis in gastric cancer and the search for new potential therapeutic targets.
Angiogenic factor with G-patch and FHA domain1 (AGGF1 or VG5Q), as a newly identified human angiogenic factor, was first reported by Tian et al. [3] in 2004. The gene is highly expressed in vascular endothelial cells and the encoded protein has a strong angiogenesis ability in vitro. Recent studies have found that AGGF1 is expressed in some types of malignant tumors and is closely related to tumor angiogenesis [4] [5] [6] [7] . Obviously, persistent angiogenesis, as one of the main signs of tumor, is closely related to the growth, invasion, metastasis, and recurrence of gastric cancer [1, 2] , but the expression level of AGGF1 and its prognostic value in patients with gastric cancer have not been reported.
Therefore, in the present study, the protein expression levels of AGGF1 and vascular endothelial growth factor (VEGF) were examined by immunohistochemistry in GC and corresponding noncancerous samples. Next, Kaplan-Meier curves and log rank test were applied to analyze the survival rate. Lastly, Cox regression method was used to explore the prognostic value of AGGF1 in gastric cancer.
Material and Methods

Patient and clinicopathologic data
We selected specimens from 198 cases of gastric cancer (GC), along with the corresponding noncancerous tissues, from patients diagnosed at the Anhui Provincial Hospital of Anhui Medical University (Hefei, China) between 2007 and 2011. Detailed pathological and clinical data (including age, sex, tumor size, Borrmann type, degree of differentiation, histological type, metastasis of lymph node, invasion depth, and TNM staging) were obtained from each patient's medical records. The samples were obtained from 58 female and 140 male patients with an average age of 56±13 years old (range, 26-82 years). None of the patients had received radiotherapy or chemotherapy before surgery. The specimens were fixed in formalin and embedded in paraffin for pathological analysis and confirmation of the diagnosis. Complete clinical follow-up data was obtained from the gastric cancer database of our hospital. The study was approved by the Anhui Medical University Human Research Ethics Committee. Written informed consent was obtained from each patient.
Immunohistochemical study
Immunohistochemistry for AGGF1 and VEGF (both antibody concentrations were 1: 500) was performed on each cancerous and corresponding noncancerous tissue. The samples (4-μm thick) were cut onto salinized glass slides consecutively. Two-step immunohistochemistry was used to detect these proteins expression according to the manufacturer's instructions.
Every section was scored on the basis of the stained tumor cells fraction and staining intensity. The proportion was classified as 0 (£1%), 1 (2% to 25%), 2 (26% to 50%), 2 (51% to 75%), and 4 (³76%). The staining intensity was scored as 0 (no staining), 1 (weak), 2 (moderate), and 3 (strong). The expression result was calculated according to the formula: percentage score multiplied by intensity score. Total scores (0-12) were categorized as low (score 0-3) or high (score [4] [5] [6] [7] [8] [9] [10] [11] [12] 
Results
AGGF1 expression in cancerous and noncancerous gastric tissues
In total, 198 paired cancerous and noncancerous tissue samples were analyzed by immunohistochemistry for AGGF1 expression. The AGGF1 immunoreactivity was mainly observed in the cytoplasm of neoplastic cells. High expression of AGGF1 was found in most cancer samples (132/198) and in fewer noncancerous samples (48/198). The expression level of AGGF1 in gastric cancer was dramatically higher than that in noncancerous samples (P<0.001). Representative GC samples with different AGGF1 expression patterns are shown in Figure 1 . 
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Correlation of AGGF1 with clinicopathological factors and VEGF
As shown in Table 1 , the expression of AGGF1 was remarkably associated with lymph node metastasis (P=0.022), invasion depth (P=0.006), and TNM stage (P<0.001). Additionally, we also found there was a significantly positive correlation between VEGF and AGGF1 expression in gastric cancer samples (P=0.017, Figure 2 ).
Correlation of AGGF1 with patients' prognosis
Kaplan-Meier method was plotted to compare the OS and DFS according to AGGF1 expression patterns. Patients with high-expression tumors showed a more unfavorable prognosis than those with low-expression tumors ( Figure 3 
Discussion
Since the gene was first reported, AGGF1 and its physiological functions were further revealed, especially in the cardiovascular system. Chen et al. [8] explored the function of AGGF1 in the angiogenesis of zebrafish and found that AGGF1 regulated the formation of blood vessels and the differentiation of veins. Lu et al. [9] administered the angiogenic therapy in a mouse hindlimb ischemia model by using AGGF1 gene, which improved blood supply to the ischemic area. Another study found that AGGF1 inhibits vascular inflammatory response and improves endothelial function [10] . Based on these findings, we speculate that AGGF1 plays an important role in the growth, metastasis, and invasion of gastric cancer. We found the expression level of AGGF1 protein was significantly higher in gastric cancer tissue than that in the corresponding noncancerous tissue. Similar to our results, a recent study found that hepatocellular carcinoma also displays overexpression of AGGF1 [7] . Furthermore, patients with high AGGF1 expression had dramatically lower DFS and OS than those with low AGGF1 expression. Additionally, high AGGF1 expression in patients with gastric cancer was closely related to poor prognosis, as demonstrated by univariate and multivariate analyses.
Tumor angiogenesis plays a pivotal role in the progression and development of gastric cancer. Overexpression of VEGF is associated with unfavorable prognosis and aggressive behavior of tumors [11] . Moreover, several studies have demonstrated that increased VEGF expression and microvessel density (MVD) are strongly related to worse prognosis in gastric cancer patients [12] [13] [14] [15] . Therefore, to explore the role of AGGF1 in angiogenesis of gastric cancer, we explored the relationships between VEGF and AGGF1 expression levels in GC tissues. We also found a significantly positive relationship between AGGF1 and VEGF expressions in gastric cancer tissues, suggesting that AGGF1, probably cooperating with VEGF, is involved in tumor angiogenesis of gastric cancer. The potential underlying mechanisms may be that AGGF1 induces the expression of VEGF through b-catenin-dependent signaling [4] .
However, some limitations should be acknowledged in this study. Firstly, it was a retrospective study with relatively small samples. Secondly, we only used immunohistochemical method to examine the protein expression levels of AGGF1 and VEGF in gastric cancer tissues, and the gene expression level was not assessed. Lastly, the exact underlying mechanisms in the participation of AGGF1 in angiogenesis of gastric cancer need to be further explored.
Conclusions
In summary, our preliminary results show that AGGF1 protein is overexpressed in gastric cancer tissues and it can be used as an independent parameter to evaluate and predict the postoperative survival time of gastric cancer patients. The potential mechanism is probably related to the promotion of tumor angiogenesis. In future, targeting AGGF1 for the inhibition of angiogenesis may be a new therapeutic strategy for gastric cancer patients.
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